Skip to content

Investigating the Effectiveness of Curcumin on Cognitive functions, Anxiety, Stress, Depression and Dependence in Substance Induced Psychotic Disorder

Investigating the Effectiveness of Curcumin on Cognitive functions, Anxiety, Stress, Depression and Dependence in Substance Induced Psychotic Disorder

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20251207068239N1
Enrollment
66
Registered
2026-01-23
Start date
2026-02-20
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance Induced Psychotic Disorder. Other stimulant dependence with stimulant-induced psychotic disorder, unspecified

Interventions

Intervention 1: Intervention group: The patients are substance induced psychotic disorder based on the final diagnosis of psychiatrist. In the intervention group, in addition to the usual medication t

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: SCID-5-CV diagnostic criteria for substance-induced psychotic disorder Having at least eighth grade education The patient is not in the acute phase of the disease. Complete the written consent form for participation in the research (Appendix One: Consent Form for Participation in the Research)

Exclusion criteria

Exclusion criteria: There is no brain injury, dementia, or specific neurological disease that requires special care. Do not receive electroshock during the treatment period. If the patient receives electroshock during the treatment for any reason, he/she will be excluded from the study. Lack of availability during the investigation Severe physical illnesses such as cancer Severe organic brain disorder according to patient self-report Concurrent participation in other psychotherapy Hypersensitivity to curcumin or any of the ingredients in the placebo If during the study the patient experiences drug side effects or needs medication that interacts with curcumin, he/she will be excluded from the study. Taking medications that interact with curcumin

Design outcomes

Primary

MeasureTime frame
Anxiety, stress, depression, dependance ,cognitive function. Timepoint: weeks 0,2,4. Method of measurement: wechsler scale , dass-21sacle ,Leeds dependance questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirAli Moghaddam Sadegh

Ahvaz University of Medical Sciences

moghaddam.a@ajums.ac.ir+98 61 3320 4637

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026